Latest updates.

€3 million European programme backs Atrogi's first-in-class drug in FSHD and other muscle-wasting diseases

The oral drug reduced DUX4 in FSHD patient muscle cells and increased lean mass and muscle power in a human study • Targets the cause: reduced DUX4 and its target genes in FSHD patient-derived muscle cells, pointing to disease-modifying potential • Builds muscle: +0.8 kg lean mass and about 13% more lower-extremity muscle power in an eight-week human study • €3 million Eurostars programme led by Atrogi in collaboration with LUMC, Karolinska Institutet, Stockholm University, Optics11 Life and NIRI

Atrogi announces positive human data for ATR-258, its first-in-class, oral therapy designed to improve muscle function and body composition

• In the 8-week study, ATR-258 was well-tolerated and associated with an approximately 13% mean improvement in lower extremity muscle power in combination with a beneficial effect on body composition, with an increase in lean muscle mass and a reduction in fat mass • Data provide first human proof-of-mechanism and support Atrogi’s planned Phase 2 trial expected to initiate in 2027

Atrogi announces first subjects dosed in human trial for lead candidate ATR-258

Atrogi’s breakthrough technology, validated by publication of landmark research in Cell in June 2025, enables, for the first time, development of next-generation, highly selective β2-agonists for chronic use

Atrogi Appoints Paul Little, PhD, as Chief Executive Officer to Accelerate Growth and Advance Next Phase

Cell Paper: GRK-biased adrenergic agonists for T2D and obesity (Motso et al.)

Motso et al. · June 2025 · Cell 188(19):5142–5156.e23